Assignee
AMGEN RES MUNICH GMBH
DE·51 granted patents·44 pending applications·407 citations·filing 2012–2025
Top patents by PatentIndex Score
95 records- 0198US9340621B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted May 17, 2016·91 cites·15 claims
- 0297US10294300B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted May 21, 2019·37 cites·16 claims
- 0397US9150664B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Oct 6, 2015·64 cites·15 claims
- 0496US11591396B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2020·Granted Feb 28, 2023·5 cites·33 claims
- 0595US11472886B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted Oct 18, 2022·3 cites·13 claims
- 0695US10301391B2BCMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted May 28, 2019·28 cites·19 claims
- 0794US9598500B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Mar 21, 2017·22 cites·15 claims
- 0893US10683351B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 16, 2020·4 cites·24 claims
- 0993US10519241B2Antibody constructs for EGFRVIII and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Dec 31, 2019·16 cites·22 claims
- 1092US10781264B2PSMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted Sep 22, 2020·8 cites·22 claims
- 1192US10766969B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2012·Granted Sep 8, 2020·8 cites·29 claims
- 1292US9982063B2Pharmaceutical compositions with resistance to soluble CEAAMGEN RES MUNICH GMBH·Filed 2016·Granted May 29, 2018·14 cites·25 claims
- 1391US11692031B2Antibody constructs for CLDN18.2 and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Jul 4, 2023·6 cites·18 claims
- 1491US11434302B2Bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2017·Granted Sep 6, 2022·7 cites·19 claims
- 1590US10752694B2Binding molecules for BCMA and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 25, 2020·11 cites·15 claims
- 1690US9688760B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Jun 27, 2017·17 cites·10 claims
- 1789US11084876B2Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domainsAMGEN RES MUNICH GMBH·Filed 2017·Granted Aug 10, 2021·4 cites·14 claims
- 1889US10662243B2Dosage regimen for administering a CD19XCD3 bispecific antibodyAMGEN RES MUNICH GMBH·Filed 2014·Granted May 26, 2020·6 cites·20 claims
- 1988US11987633B2Cross-species-specific single domain bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted May 21, 2024·1 cites·27 claims
- 2087US11661462B2Optimized cross-species specific bispecific single chain antibody contructsAMGEN RES MUNICH GMBH·Filed 2015·Granted May 30, 2023·4 cites·12 claims
- 2187US11597766B2Treatment of acute lymphoblastic leukemiaAMGEN RES MUNICH GMBH·Filed 2018·Granted Mar 7, 2023·8 cites·21 claims
- 2287US10059766B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Aug 28, 2018·9 cites·17 claims
- 2386US11447567B2Antibody constructs for FLT3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Sep 20, 2022·4 cites·18 claims
- 2486US11155629B2Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3AMGEN RES MUNICH GMBH·Filed 2019·Granted Oct 26, 2021·2 cites·20 claims
- 2584US12435139B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2022·Granted Oct 7, 2025·0 cites·12 claims
- 2684US11352433B2BCMA and CD3 bispecific T cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2019·Granted Jun 7, 2022·2 cites·23 claims
- 2784US10696744B2Means and methods for treating DLBCLAMGEN RES MUNICH GMBH·Filed 2015·Granted Jun 30, 2020·3 cites·13 claims
- 2883US10047159B2Bispecific single chain antibodies with specificity for high molecular weight target antigensAMGEN RES MUNICH GMBH·Filed 2016·Granted Aug 14, 2018·3 cites·18 claims
- 2983US2025064927A1Compositions comprising cross-species-specific antibodies and uses thereofAMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 3083US2025340639A1Antibody constructs for dll3 and cd3AMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 3182US10851170B2Antibody constructs for CD70 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Dec 1, 2020·3 cites·18 claims
- 3280US9695250B2Pharmaceutical compositions with resistance to soluble CEAAMGEN RES MUNICH GMBH·Filed 2013·Granted Jul 4, 2017·4 cites·19 claims
- 3379US11498964B2Antibody constructs for CDH19 and CD3AMGEN RES MUNICH GMBH·Filed 2018·Granted Nov 15, 2022·1 cites·17 claims
- 3478US9486475B2PPS for the prevention of potential adverse effects caused by CD3 specific binding domainsAMGEN RES MUNICH GMBH·Filed 2014·Granted Nov 8, 2016·4 cites·14 claims
- 3578US2024166761A1Single chain binding molecules comprising N-terminal ABPAMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 3678US2024400673A1Antibody constructs for msln and cd3AMGEN RES MUNICH GMBH·Filed 2023·Application pending·0 cites
- 3776US12304952B2Antibody constructs for DLL3 and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted May 20, 2025·0 cites·16 claims
- 3876US2025092133A1Bispecific antibody constructs for cdh3 and cd3AMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 3975US12281172B2Cross-species-specific PSMAxCD3 bispecific single chain antibodyAMGEN RES MUNICH GMBH·Filed 2021·Granted Apr 22, 2025·0 cites·18 claims
- 4075US12152078B2Nucleic acids encoding anitbody constructs binding EGFR VIII and CD3AMGEN RES MUNICH GMBH·Filed 2021·Granted Nov 26, 2024·0 cites·24 claims
- 4175US2025333535A1Bispecific single chain antibody construct with enhanced tissue distributionAMGEN RES MUNICH GMBH·Filed 2024·Application pending·0 cites
- 4274US11884720B2Antibody constructs for MSLN and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Jan 30, 2024·1 cites·23 claims
- 4374US2025163179A1CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODYAMGEN RES MUNICH GMBH·Filed 2025·Application pending·0 cites
- 4473US8658172B2Treatment of metastatic breast cancerAMGEN RES MUNICH GMBH·Filed 2012·Granted Feb 25, 2014·2 cites·6 claims
- 4572US9919051B2Liquid formulation comprising GM-CSF neutralizing compoundAMGEN RES MUNICH GMBH·Filed 2013·Granted Mar 20, 2018·2 cites·23 claims
- 4672US2023057728A1Long life polypeptide binding moleculesAMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 4772US2023192884A1Bispecific t cell engaging antibody constructsAMGEN RES MUNICH GMBH·Filed 2022·Application pending·0 cites
- 4871US11925684B2Compositions comprising cross-species-specific antibodies and uses thereofAMGEN RES MUNICH GMBH·Filed 2018·Granted Mar 12, 2024·0 cites·16 claims
- 4970US11028171B2Bispecific antibody constructs for CDH3 and CD3AMGEN RES MUNICH GMBH·Filed 2016·Granted Jun 8, 2021·1 cites·14 claims
- 5070US9505849B2Antibody constructs for influenza M2 and CD3AMGEN RES MUNICH GMBH·Filed 2014·Granted Nov 29, 2016·1 cites·20 claims
Showing the top 50 of 95 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when AMGEN RES MUNICH GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →